<DOC>
	<DOC>NCT02644616</DOC>
	<brief_summary>The investigators research the early improvement of fluid retention and mid-term prognosis through the administration of tolvaptan for the patient with tricuspid regurgitation and right heart failure after left heart valves replacement.</brief_summary>
	<brief_title>The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Tricuspid Valve Insufficiency</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<mesh_term>Torsemide</mesh_term>
	<criteria>1. Patient with tricuspid regurgitation and right heart failure after left heart valves replacement 2. Patients who takes existing diuretic 3. The patient is willing to participate in the study 1. Patients with hypersensitivity to study drug 2. Anuric patients 3. Patients with hypernatremia 4. Female patients who are pregnant, possibly pregnant, or lactating, or who plan to become pregnant 5. Malignant tumor 6. Patients with serious hepatic disorder or Serious Renal failure 7. Patients otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>tolvaptan</keyword>
	<keyword>safety and efficacy</keyword>
	<keyword>left heart valves replacement</keyword>
</DOC>